search
Back to results

SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease (NOTOXIS)

Primary Purpose

Hearing Loss Ototoxic

Status
Recruiting
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
SENS-401 (R-Azasetron Besylate)
Sponsored by
Sensorion
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Hearing Loss Ototoxic

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age ≥ 18 years at the time of signing the ICF. Neoplastic subject that regardless of participation in this study is planned to be treated with a chemotherapy that includes a dose of cisplatin of at least 70 mg/m² per cycle and a cumulative dose of cisplatin of at least 210 mg/m². Exclusion Criteria: Any condition or past medical history that, in the opinion of the Investigator, may compromise the safety or compliance of the subject or would preclude the subject from successful completion of the study. A congenital or hereditary disease known to decrease hearing function. Any medical history affecting the middle ear function such as chronic otitis, cholesteatoma, or tympanic membrane perforation. Any inner ear disease that is likely to decrease hearing function according to the Investigator's judgment (e.g, herpes zoster oticus; Meniere's disease; purulent labyrinthitis; vestibular schwannoma). Having a history of sudden sensory neural hearing loss. Having a fluctuating hearing loss (e.g, due to Meniere's disease, vestibular aqueduct syndrome, or autoimmune inner ear disease). History of head trauma with hearing loss. History of meningitis. Having received concomitant treatment known or suspected to induce an ototoxicity within 6 months prior to Screening (i.e, aminoglycosides, loop diuretics, quinine) and any other treatments listed in Appendix 5. Previous treatment with a platinum treatment should be considered as an exclusion criterion.

Sites / Locations

  • Hôpital Henri MondorRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Study Arm A (control arm)

Study Arm B (treatment arm)

Arm Description

Subjects receiving cisplatin-based chemotherapy without receiving SENS-401. This control arm will provide natural history data, particularly the incidence and the time to onset of hearing impairment due to ototoxicity.

Subjects receiving 43.5 mg of oral SENS-401 b.i.d for up to 23 weeks. This arm will provide data on the potential protective effects of SENS-401 on cisplatin induced ototoxicity.

Outcomes

Primary Outcome Measures

SENS-401 efficacy assessment with change from baseline of the average of the hearing threshold 4 weeks after the completion of cisplatin treatment
Change from baseline of the average of the hearing threshold of 3 contiguous hearing frequencies assessed with a 0.5-12.5 kHz audiogram 4 weeks after the completion of the last cisplatin treatment in each ear of each subject.

Secondary Outcome Measures

SENS-401 efficacy assessment with change from baseline of the average of the hearing threshold 12 weeks after the completion of cisplatin treatment.
Change from baseline of the average of the hearing threshold of 3 contiguous hearing frequencies assessed with a 0.5-12.5 kHz audiogram 12 weeks after the completion of the last cisplatin treatment in each ear of each subject.
SENS-401 efficacy assessment with change from baseline in the distribution of hearing loss severity 4 weeks after the completion of cisplatin treatment
Change from baseline in the distribution of hearing loss severity at 4 weeks after the completion of cisplatin treatment. The severity of the hearing loss being based on the CTCAE (version 5.0).
SENS-401 efficacy assessment with change from baseline in the distribution of hearing 12 weeks after the completion of cisplatin treatment
Change from baseline in the distribution of hearing loss severity at 12 weeks after the completion of cisplatin treatment. The severity of the hearing loss being based on the CTCAE (version 5.0).
SENS-401 efficacy assessment with change from baseline in speech discrimination test score 4 weeks after the completion of cisplatin treatment.
Change from baseline in speech discrimination test score (assessed in noise and in quiet) 4 weeks after the completion of the cisplatin treatment.
SENS-401 efficacy assessment with change from baseline in speech discrimination test score 12 weeks after the completion of cisplatin treatment
Change from baseline in speech discrimination test score (assessed in noise and in quiet) 12 weeks after the completion of the cisplatin treatment.
SENS-401 efficacy assessment with change from baseline in Tinnitus Handicap Inventory (THI) Questionnaire score 4 weeks after the completion of cisplatin treatment.
Change from baseline in Tinnitus Handicap Inventory (THI) Questionnaire score, 4 weeks after the completion of the cisplatin treatment.
SENS-401 efficacy assessment with change from baseline in Tinnitus Handicap Inventory (THI) Questionnaire score 12 weeks after the completion of cisplatin treatment
Change from baseline in Tinnitus Handicap Inventory (THI) Questionnaire score,12 weeks after the completion of the cisplatin treatment.

Full Information

First Posted
November 16, 2022
Last Updated
March 2, 2023
Sponsor
Sensorion
search

1. Study Identification

Unique Protocol Identification Number
NCT05628233
Brief Title
SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease
Acronym
NOTOXIS
Official Title
A Phase IIa, Multicenter, Randomized, Controlled, Open Label Study to Evaluate the Efficacy of SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 30, 2022 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
August 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sensorion

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is intended to evaluate the ability of SENS-401 to prevent the ototoxicity induced by cisplatin in subjects with a neoplastic disease. It is a multicenter, randomized, controlled, two-arm, open-label efficacy and safety study in adults with neoplastic disease requiring treatment with cisplatin as part of the chemotherapy protocol plan.
Detailed Description
This study is intended to evaluate the ability of SENS-401 to prevent the ototoxicity induced by cisplatin in subjects with a neoplastic disease. It is a multicenter, randomized, controlled, two-arm, open-label efficacy and safety study in adults with neoplastic disease requiring treatment with cisplatin as part of the chemotherapy protocol plan. Cisplatin treatment per chemotherapy protocol must be given at a cumulative dose high enough to significantly increase the iatrogenic likelihood of ototoxicity (unit cisplatin dose of at least 70 mg/m2 and cumulative cisplatin dose of at least 210 mg/m²). If all the eligibility criteria are met, subjects will be randomized to one of two study arms as follows: Study Arm A (control arm): Subjects receiving cisplatin-based chemotherapy without receiving SENS-401. This control arm will provide natural history data, particularly the incidence and the time to onset of hearing impairment due to ototoxicity. Study Arm B: Subjects receiving 43.5 mg of oral SENS-401 b.i.d for up to 23 weeks: 1 week prior to the initiation of the cisplatin treatment, during the whole duration of the chemotherapy treatment (estimated to last up to 18 weeks) and 4 weeks after stopping chemotherapy. This arm will provide data on the potential protective effects of SENS-401 on cisplatin induced ototoxicity. All subjects will be followed up to 12 weeks after the completion of the cisplatin therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hearing Loss Ototoxic

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
58 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Study Arm A (control arm)
Arm Type
No Intervention
Arm Description
Subjects receiving cisplatin-based chemotherapy without receiving SENS-401. This control arm will provide natural history data, particularly the incidence and the time to onset of hearing impairment due to ototoxicity.
Arm Title
Study Arm B (treatment arm)
Arm Type
Experimental
Arm Description
Subjects receiving 43.5 mg of oral SENS-401 b.i.d for up to 23 weeks. This arm will provide data on the potential protective effects of SENS-401 on cisplatin induced ototoxicity.
Intervention Type
Drug
Intervention Name(s)
SENS-401 (R-Azasetron Besylate)
Intervention Description
Patients will receive SENS-401 ((R)-azasetron besylate) B.I.D. up to 23 weeks: 1 week prior to the initiation of the cisplatin treatment, during the whole duration of the chemotherapy treatment (estimated to last up to 18 weeks) and 4 weeks after stopping chemotherapy.
Primary Outcome Measure Information:
Title
SENS-401 efficacy assessment with change from baseline of the average of the hearing threshold 4 weeks after the completion of cisplatin treatment
Description
Change from baseline of the average of the hearing threshold of 3 contiguous hearing frequencies assessed with a 0.5-12.5 kHz audiogram 4 weeks after the completion of the last cisplatin treatment in each ear of each subject.
Time Frame
23 weeks
Secondary Outcome Measure Information:
Title
SENS-401 efficacy assessment with change from baseline of the average of the hearing threshold 12 weeks after the completion of cisplatin treatment.
Description
Change from baseline of the average of the hearing threshold of 3 contiguous hearing frequencies assessed with a 0.5-12.5 kHz audiogram 12 weeks after the completion of the last cisplatin treatment in each ear of each subject.
Time Frame
31 weeks
Title
SENS-401 efficacy assessment with change from baseline in the distribution of hearing loss severity 4 weeks after the completion of cisplatin treatment
Description
Change from baseline in the distribution of hearing loss severity at 4 weeks after the completion of cisplatin treatment. The severity of the hearing loss being based on the CTCAE (version 5.0).
Time Frame
23 weeks
Title
SENS-401 efficacy assessment with change from baseline in the distribution of hearing 12 weeks after the completion of cisplatin treatment
Description
Change from baseline in the distribution of hearing loss severity at 12 weeks after the completion of cisplatin treatment. The severity of the hearing loss being based on the CTCAE (version 5.0).
Time Frame
31 weeks
Title
SENS-401 efficacy assessment with change from baseline in speech discrimination test score 4 weeks after the completion of cisplatin treatment.
Description
Change from baseline in speech discrimination test score (assessed in noise and in quiet) 4 weeks after the completion of the cisplatin treatment.
Time Frame
23 weeks
Title
SENS-401 efficacy assessment with change from baseline in speech discrimination test score 12 weeks after the completion of cisplatin treatment
Description
Change from baseline in speech discrimination test score (assessed in noise and in quiet) 12 weeks after the completion of the cisplatin treatment.
Time Frame
31 weeks
Title
SENS-401 efficacy assessment with change from baseline in Tinnitus Handicap Inventory (THI) Questionnaire score 4 weeks after the completion of cisplatin treatment.
Description
Change from baseline in Tinnitus Handicap Inventory (THI) Questionnaire score, 4 weeks after the completion of the cisplatin treatment.
Time Frame
23 weeks
Title
SENS-401 efficacy assessment with change from baseline in Tinnitus Handicap Inventory (THI) Questionnaire score 12 weeks after the completion of cisplatin treatment
Description
Change from baseline in Tinnitus Handicap Inventory (THI) Questionnaire score,12 weeks after the completion of the cisplatin treatment.
Time Frame
31 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years at the time of signing the ICF. Neoplastic subject that regardless of participation in this study is planned to be treated with a chemotherapy that includes a dose of cisplatin of at least 70 mg/m² per cycle and a cumulative dose of cisplatin of at least 210 mg/m². Exclusion Criteria: Any condition or past medical history that, in the opinion of the Investigator, may compromise the safety or compliance of the subject or would preclude the subject from successful completion of the study. A congenital or hereditary disease known to decrease hearing function. Any medical history affecting the middle ear function such as chronic otitis, cholesteatoma, or tympanic membrane perforation. Any inner ear disease that is likely to decrease hearing function according to the Investigator's judgment (e.g, herpes zoster oticus; Meniere's disease; purulent labyrinthitis; vestibular schwannoma). Having a history of sudden sensory neural hearing loss. Having a fluctuating hearing loss (e.g, due to Meniere's disease, vestibular aqueduct syndrome, or autoimmune inner ear disease). History of head trauma with hearing loss. History of meningitis. Having received concomitant treatment known or suspected to induce an ototoxicity within 6 months prior to Screening (i.e, aminoglycosides, loop diuretics, quinine) and any other treatments listed in Appendix 5. Previous treatment with a platinum treatment should be considered as an exclusion criterion.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marion Laborie, MSc
Phone
+33 (0) 7 86 91 83 38
Email
marion.laborie@sensorion-pharma.com
First Name & Middle Initial & Last Name or Official Title & Degree
Géraldine Honnet, MD
Email
geraldine.honnet@sensorion-pharma.com
Facility Information:
Facility Name
Hôpital Henri Mondor
City
Créteil
ZIP/Postal Code
94010
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christophe Tournigand, M.D.
Phone
+ 33 5 56 33 33 33

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease

We'll reach out to this number within 24 hrs